Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Adults With Nonalcoholic Steatohepatitis (NASH)
The primary objective of this study is to evaluate the safety and tolerability of study drug(s) in adults with nonalcoholic steatohepatitis (NASH).
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)
Estimated Study Start Date: August 2019
Estimated Primary Completion Date: June 2020
Estimated Study Completion Date: July 2020
Arms:
- Experimental: Semaglutide
- Experimental: Semaglutide + Firsocostat
- Experimental: Semaglutide + Cilofexor 30 mg
- Experimental: Semaglutide + Cilofexor 100 mg
- Experimental: Semaglutide + Firsocostat + Cilofexor
| Category | Value |
|---|---|
| Date last updated at source | 2019-07-17 |
| Study type(s) | Interventional |
| Expected enrolment | 100 |
| Study start date | 2019-08-01 |
| Estimated primary completion date | 2020-06-01 |